Your browser doesn't support javascript.
loading
Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting.
Aguirre, Andrew J; Meyers, Robin M; Weir, Barbara A; Vazquez, Francisca; Zhang, Cheng-Zhong; Ben-David, Uri; Cook, April; Ha, Gavin; Harrington, William F; Doshi, Mihir B; Kost-Alimova, Maria; Gill, Stanley; Xu, Han; Ali, Levi D; Jiang, Guozhi; Pantel, Sasha; Lee, Yenarae; Goodale, Amy; Cherniack, Andrew D; Oh, Coyin; Kryukov, Gregory; Cowley, Glenn S; Garraway, Levi A; Stegmaier, Kimberly; Roberts, Charles W; Golub, Todd R; Meyerson, Matthew; Root, David E; Tsherniak, Aviad; Hahn, William C.
Afiliación
  • Aguirre AJ; Dana-Farber Cancer Institute, Boston, Massachusetts. Broad Institute of Harvard and MIT, Cambridge, Massachusetts. Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts.
  • Meyers RM; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Weir BA; Dana-Farber Cancer Institute, Boston, Massachusetts. Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Vazquez F; Dana-Farber Cancer Institute, Boston, Massachusetts. Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Zhang CZ; Dana-Farber Cancer Institute, Boston, Massachusetts. Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Ben-David U; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Cook A; Dana-Farber Cancer Institute, Boston, Massachusetts. Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Ha G; Dana-Farber Cancer Institute, Boston, Massachusetts. Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Harrington WF; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Doshi MB; Dana-Farber Cancer Institute, Boston, Massachusetts. Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Kost-Alimova M; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Gill S; Dana-Farber Cancer Institute, Boston, Massachusetts. Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Xu H; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Ali LD; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Jiang G; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Pantel S; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Lee Y; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Goodale A; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Cherniack AD; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Oh C; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Kryukov G; Dana-Farber Cancer Institute, Boston, Massachusetts. Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Cowley GS; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Garraway LA; Dana-Farber Cancer Institute, Boston, Massachusetts. Broad Institute of Harvard and MIT, Cambridge, Massachusetts. Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts. Howard Hughes Medical Institute, C
  • Stegmaier K; Dana-Farber Cancer Institute, Boston, Massachusetts. Broad Institute of Harvard and MIT, Cambridge, Massachusetts. Harvard Medical School, Boston, Massachusetts. Boston Children's Hospital, Boston, Massachusetts.
  • Roberts CW; Broad Institute of Harvard and MIT, Cambridge, Massachusetts. St. Jude Children's Research Hospital, Memphis, Tennessee.
  • Golub TR; Dana-Farber Cancer Institute, Boston, Massachusetts. Broad Institute of Harvard and MIT, Cambridge, Massachusetts. Harvard Medical School, Boston, Massachusetts. Howard Hughes Medical Institute, Chevy Chase, Maryland.
  • Meyerson M; Dana-Farber Cancer Institute, Boston, Massachusetts. Broad Institute of Harvard and MIT, Cambridge, Massachusetts. Harvard Medical School, Boston, Massachusetts. Department of Pathology, Harvard Medical School, Boston, Massachusetts. Center for Cancer Genome Discovery, Dana-Farber Cancer Institute,
  • Root DE; Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
  • Tsherniak A; Broad Institute of Harvard and MIT, Cambridge, Massachusetts. william_hahn@dfci.harvard.edu aviad@broadinstitute.org.
  • Hahn WC; Dana-Farber Cancer Institute, Boston, Massachusetts. Broad Institute of Harvard and MIT, Cambridge, Massachusetts. Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Harvard Medical School, Boston, Massachusetts. Center for Cancer Genome Discovery
Cancer Discov ; 6(8): 914-29, 2016 08.
Article en En | MEDLINE | ID: mdl-27260156
ABSTRACT
UNLABELLED The CRISPR/Cas9 system enables genome editing and somatic cell genetic screens in mammalian cells. We performed genome-scale loss-of-function screens in 33 cancer cell lines to identify genes essential for proliferation/survival and found a strong correlation between increased gene copy number and decreased cell viability after genome editing. Within regions of copy-number gain, CRISPR/Cas9 targeting of both expressed and unexpressed genes, as well as intergenic loci, led to significantly decreased cell proliferation through induction of a G2 cell-cycle arrest. By examining single-guide RNAs that map to multiple genomic sites, we found that this cell response to CRISPR/Cas9 editing correlated strongly with the number of target loci. These observations indicate that genome targeting by CRISPR/Cas9 elicits a gene-independent antiproliferative cell response. This effect has important practical implications for the interpretation of CRISPR/Cas9 screening data and confounds the use of this technology for the identification of essential genes in amplified regions.

SIGNIFICANCE:

We found that the number of CRISPR/Cas9-induced DNA breaks dictates a gene-independent antiproliferative response in cells. These observations have practical implications for using CRISPR/Cas9 to interrogate cancer gene function and illustrate that cancer cells are highly sensitive to site-specific DNA damage, which may provide a path to novel therapeutic strategies. Cancer Discov; 6(8); 914-29. ©2016 AACR.See related commentary by Sheel and Xue, p. 824See related article by Munoz et al., p. 900This article is highlighted in the In This Issue feature, p. 803.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Marcación de Gen / Dosificación de Gen / Genómica / Repeticiones Palindrómicas Cortas Agrupadas y Regularmente Espaciadas / Sistemas CRISPR-Cas Límite: Humans Idioma: En Revista: Cancer Discov Año: 2016 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Marcación de Gen / Dosificación de Gen / Genómica / Repeticiones Palindrómicas Cortas Agrupadas y Regularmente Espaciadas / Sistemas CRISPR-Cas Límite: Humans Idioma: En Revista: Cancer Discov Año: 2016 Tipo del documento: Article